New diabetes drug HMS1005 enters first human tests
NCT ID NCT07568678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, HMS1005, in 40 people with type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. Researchers will also look at how it affects blood sugar levels over 24 hours. Participants will receive either the drug or a placebo, and neither they nor the doctors will know who gets what.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HMS1005
What this could lead to
If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early phase 1 trial with only 40 participants, so it is primarily checking safety. The drug may not work well or could have side effects. Much more testing is needed before it could become a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Pharmacology of Miami
RECRUITINGMiami, Florida, 33172, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••